Reconstituted immunity against persistent parvovirus B19 infection in a patient with acquired immunodeficiency syndrome after highly active antiretroviral therapy
Journal
Clinical Infectious Diseases
Journal Volume
32
Journal Issue
9
Pages
1361-1365
Date Issued
2001
Author(s)
Abstract
We discovered a patient with AIDS with persistent B19 infection who had slow resolution of anemia after he commenced receiving HAART without intravenous immunoglobulin. The patient's anemia recurred when the initial course of HAART failed, but it remitted slowly after salvage therapy was instituted. However, circulating B19 was still detectable by nested polymerase chain reaction 1 year after commencement of salvage therapy. Immunoglobulin G and immunoglobulin M antibodies against B19 were not detected by means of enzyme-linked immunosorbent assay when the anemia initially resolved, but they were detected after the patient commenced receiving salvage therapy. The absence of antibody response after the initial remission of parvovirus B 19 infection suggested that cellular immunity was an important component of reconstituted immune function against B19 after the patient received HAART. The humoral response that was restored later was abnormal; it had strong reactivity to nonstructural protein NS-1 and poor generation of neutralizing antibodies against linear epitopes unique to minor capsid protein VP1. ? 2001 the Infectious Diseases Society of America.
SDGs
Other Subjects
antiretrovirus agent; capsid protein; CD4 antigen; epitope; ganciclovir; hemoglobin; immunoglobulin; immunoglobulin G antibody; immunoglobulin M antibody; lamivudine; neutralizing antibody; saquinavir; virus DNA; virus RNA; zalcitabine; zidovudine; acquired immune deficiency syndrome; adult; anemia; antibody response; article; case report; enzyme linked immunosorbent assay; human; immunity; immunoblotting; leukopenia; male; Parvovirus; polyacrylamide gel electrophoresis; polymerase chain reaction; priority journal; virus infection; virus load; Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; DNA, Viral; Enzyme-Linked Immunosorbent Assay; HIV-1; Humans; Immunoblotting; Male; Parvoviridae Infections; Parvovirus B19, Human; Polymerase Chain Reaction; RNA, Viral; Viral Load; Virus Latency
Type
journal article